DISEASE CHARACTERISTICS:

• Women with histologically documented metastatic carcinoma of the breast

  • Bilateral disease allowed
  • Concurrent intraductal or lobular carcinoma in situ allowed

• Measurable or evaluable recurrent metastatic disease (stage IV) documented by radiograph, CT scan, nuclear medicine scan, or physical exam

  • Biopsy of recurrent site(s) recommended but not required
  • Nonmeasurable disease allowed if tumor or metastatic disease has been previously removed or successfully treated
• 0 to 3+ HER2 amplification, as determined by FISH

• No clinical evidence of active brain metastases

  • Patients with treated brain metastases (i.e., those who have received definitive radiation, chemotherapy, and/or underwent surgery) and are stable are eligible

• Hormone receptor status:

  • Estrogen or progesterone receptor positive or negative

PATIENT CHARACTERISTICS:

• Menopausal status not specified
• Karnofsky performance status 70-100% OR ECOG performance status 0-2
• Life expectancy at least 3 months
• Granulocyte count at least 1,500/mm^3
• Platelet count at least 50,000/mm^3
• Hemoglobin greater than 8 g/dL
• Bilirubin less than 1.5 times normal
• AST, ALT, and alkaline phosphatase < 5 times upper normal
• Creatinine less than 1.8 mg/dL
• Creatinine clearance at least 60 mL/min
• BUN less than 1.5 times normal
• No myocardial infarction (MI) within the past year
• No history of MI (> 1 year ago) with current coronary symptoms requiring medication
• No current history of angina/coronary symptoms requiring medication
• No clinical evidence of congestive heart failure requiring medical management
• No significant congestive heart failure
• No other uncontrolled or significant cardiovascular disease
• Ejection fraction at least 45% at rest by MUGA

• Systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg

  • BP must be controlled to meet the standard by anti-hypertensive medications for at least 7 days prior to the first infusion
• PFT-FEV_1 at least 50% predicted
• DLCO2 at least 50% predicted
• FVC at least 50% predicted
• No other malignancy within the past 3 years
• No other serious medical or psychiatric illness that would preclude study participation
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Prior chemotherapy regimens allowed, including prior treatment on protocol WSU-2006-130
• Prior vaccine therapy on protocol WSU-2006-130 allowed
• More than 4 weeks to leukapheresis since prior hormonal therapy
• No radiation to the axial skeleton within 4 weeks of leukapheresis

• No concurrent hormonal therapy for breast cancer

  • Hormones administered for non-disease-related condition (e.g. insulin for diabetes) allowed
• Concurrent steroids for adrenal failure, septic shock, or pulmonary toxicity allowed